Campbell & CO Investment Adviser LLC Takes Position in CVS Health Corporation $CVS

Key Points

• Campbell & CO Investment Adviser LLC acquired a new stake of 24,270 shares in CVS Health Corporation, valuing approximately $1,644,000, according to their 13F filing with the SEC.
• CVS Health recently reported earnings per share (EPS) of $1.81, exceeding analyst expectations, with quarterly revenue growing 8.4% year-over-year to $98.92 billion.
• Multiple research analysts have upgraded CVS Health’s stock rating to "buy" and increased price targets, with a consensus price target now at $76.67.

Campbell & CO Investment Adviser LLC acquired a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 24,270 shares of the pharmacy operator's stock, valued at approximately $1,644,000.

Other institutional investors have also recently made changes to their positions in the company. Whitebox Advisors LLC purchased a new position in shares of CVS Health during the fourth quarter valued at about $249,000. Jennison Associates LLC grew its position in shares of CVS Health by 503.8% during the first quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator's stock valued at $128,477,000 after purchasing an additional 1,582,257 shares in the last quarter. Cerity Partners LLC grew its position in shares of CVS Health by 25.0% during the first quarter. Cerity Partners LLC now owns 648,266 shares of the pharmacy operator's stock valued at $43,920,000 after purchasing an additional 129,535 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of CVS Health by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator's stock valued at $608,481,000 after purchasing an additional 183,813 shares in the last quarter. Finally, Fairfax Financial Holdings Ltd. Can purchased a new position in shares of CVS Health during the fourth quarter valued at about $121,742,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Down 0.1%

Shares of NYSE CVS opened at $71.22 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The company has a market cap of $90.33 billion, a P/E ratio of 19.89, a PEG ratio of 0.79 and a beta of 0.58. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $72.51. The firm has a 50-day simple moving average of $65.57 and a two-hundred day simple moving average of $65.37.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Tuesday, July 22nd. CVS Health's payout ratio is currently 74.30%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CVS shares. UBS Group upgraded CVS Health from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $67.00 to $79.00 in a research report on Monday, August 18th. Barclays lifted their price target on CVS Health from $79.00 to $80.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, August 4th. Finally, Jefferies Financial Group lifted their price target on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $76.67.

Insider Activity

In other news, Director Guy P. Sansone purchased 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.22% of the company's stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.